Related Experiment Video
Updated: Jul 23, 2025
09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
664
The Future of Chimeric Antigen Receptor T Cell Therapy
1Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Hematology/Oncology Clinics of North America
|July 13, 2023
Abstract:
Over the last 10 years CAR T cell therapies have been shown to be transformative for B- and plasma-cell malignancies, however the field is only beginning to realize the potential benefit to patients of such therapies. Over the next 10 years it is expected that advances will be made in durable response rates for patients with B/plasma cell malignancies; expansion to T-cell, myeloid, and solid malignancies; and in delivery and manufacturing to transform the field.
